-
Sociodemographic and Occupational Factors Associated With Coronavirus Disease 2019 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022–2023: A Multicenter Study Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-06-03
Anisa Xhaferi, Silvia Bino, Rovena Daja, Adela Vasili, Jonilda Sulo, Nana Mebonia, Earta Ndreu, Miljana Nika, Nadire Jani, Ermiona Dabaj, Nensi Sustarova, Anila Moçi, Dorina Toçi, Albana Fico, Eugena Tomini, Sara Robinson, Pernille Jorgensen, Mark A KatzBackground Healthcare workers (HCWs) are a priority group for coronavirus disease 2019 (COVID-19) and influenza vaccination. We evaluated sociodemographic and occupational factors, attitudes, and knowledge associated with the uptake of primary and booster doses of COVID-19 and seasonal influenza vaccines among HCWs. Methods Between February 2022 and February 2023, we administered a structured questionnaire
-
Clinical and microbiological characteristics of meningococcal eye infections: retrospective national surveillance in England, 2010-2022 Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-06-02
Stephen A Clark, Emma Heymer, Helen Campbell, Sonia Ribeiro, Aiswarya Lekshmi, Jay Lucidarme, Xilian Bai, Shamez N Ladhani, Ray BorrowObjectives Neisseria meningitidis is primarily associated with severe systemic infections but can infect the eye and periocular tissues. Most meningococcal eye infections have a mild prognosis, but there is a significant increase in the risk of invasive disease. UK public health guidelines recommend chemoprophylaxis for meningococcal eye infection cases and contacts. This study involved a clinical
-
Kinetics and predictors of Hepatitis B surface antigen (HBsAg) loss after commencing HBV-active antiretroviral therapy (ART) in the setting of HIV-and chronic HBV co-infection Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-31
Jennifer Audsley, Anchalee Avihingsanon, Xin Li, Rosalind Edwards, Kathy Jackson, Nadia Warner, Olivia Maslac, Peter Revill, Hay Mar Su Lwin, Sivaporn Gatechompol, Nagalingeswaran Kumarasamy, Tim Spelman, Iskandar Azwa, Adeeba Kamarulzaman, Sharon R Lewin, Joe SasadeuszBackground An effective therapeutic strategy for HBV cure remains an urgent unmet need. We aimed to define the incidence, kinetics and predictors of hepatitis B surface antigen (HBsAg) loss in people living with HIV and HBV (PLWH-HBV) following HBV-active antiretroviral therapy (ART) in PLWH-HBV in Asia. Method 97 PLWH-HBV commencing HBV-active ART were recruited prospectively in Thailand (n=94) and
-
Secondary Pneumococcal Disease in Veterans with Viral Respiratory Infections Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-31
Lauren A Powers, Arthur K Chan, Bethany A Wattengel, Matthew Davis, Ashley L O’Leary, Jiachen Xu, John C Hu, Kari A MergenhagenBackground Post-viral secondary bacterial infection, such as those caused by Streptococcus pneumoniae, are strongly associated with influenza and respiratory syncytial virus (RSV). However, data evaluating this relationship with coronavirus disease 2019 (COVID-19) is limited. Methods A retrospective analysis was conducted in hospitalized patients in Veterans Affairs (VA) Hospitals across the United
-
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination with Meropenem plus Amoxicillin/Clavulanate Among Adults with Rifampicin-Resistant Pulmonary Tuberculosis Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-30
Veronique de Jager, Laurynas Mockeliunas, Huifang You, Ulrika S H Simonsson, Tarryn Collings, Caryn M Upton, Johannes A Bezuidenhout, Nikhil Gupte, Susan Dorman, Eric Nuermberger, Gyanu Lamichhane, Andreas H Diacon, Kelly E DooleyBackground In vitro, meropenem is shown to restore the activity of rifampicin in rifampicin-resistant Mycobacterium tuberculosis strains. This phase 2a trial aimed to determine if addition of rifampicin increases the early bactericidal activity (EBA) of meropenem plus amoxicillin/clavulanate in patients with rifampicin-resistant tuberculosis (RR-TB). Methods Individuals with RR-TB were randomized to
-
Interferon-γ therapy in patients with refractory disseminated coccidioidomycosis Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-29
Chen Wang, Brenna A LaBere, Michell M Lozano Chinga, Annalie J Harris, Lindsey B Rosen, Amanda Elias Rivera, Eva Le Run, Keith A Sacco, Wassim Ballan, James V Woodward, Scott A Ostdiek, Matthew W Smith, Victoria L Anderson, Janine R Daub, Cindy L Palmer, Lavenda Chirombo Kluczynski, Andrew J Oler, Magdalena A Walkiewicz, Rajarshi Ghosh, Morgan Similuk, Fariba M Donovan, John Witt, Nicolas Barros, LRefractory disseminated coccidioidomycosis (DCM) is a severe disease with limited treatment options. This report reviews our own and prior published experiences using adjunctive interferon-γ therapy in refractory DCM, showing overall favorable responses in patients without Signal Transducer and Activator of Transcription 1 gain-of-function mutations.
-
Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomised controlled trial Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-29
Susan E Purchase, Joanna Brigden, James A Seddon, Neil A Martinson, Lee Fairlie, Suzanne Staples, Thomas Wilkinson, Trinh Duong, H Simon Schaaf, Anneke C HesselingBackground Young children have a high risk of developing tuberculosis (TB) disease following infection with Mycobacterium tuberculosis (M.tb) in the absence of preventive treatment. Infection prevalence and risk factors for infection impact delivery of prevention strategies. We aimed to determine the prevalence of infection in child household contacts aged < 5 years exposed to adults with confirmed
-
Pulmonary Tuberculosis Associated Chronic Pulmonary Aspergillosis: Urgent Need to Standardize Reporting of Prevalence Studies. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-28
Felix Bongomin,David W Denning -
Low Rate of Documented Measles Immunity in a Large Urban HIV Clinic Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-28
Hayden S Andrews, Hannah L Blanchard, Shining Yang, Netanya S UtayPeople with HIV (PWH) have increased risk of complications from measles. Only 11.2% of 13,622 PWH in one U.S. clinic had presumptive measles immunity. The most significant correlates of seronegativity were younger age, white race, and CD4 count <200 cells/µL. Increasing measles immunity in PWH is essential given increasing outbreaks.
-
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY) Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-24
Cameron R Wolfe, Jonathan Cohen, Kathryn Mahoney, Anna Holmes, Natalia Betancourt, Deepali Gupta, Kazima Tosh, Kristin Narayan, Ed Campanaro, Chloe Katz, Anne-Marie Phelan, Ilker Yalcin, Mark Wingertzahn, Pamela Hawn, Pete Schmidt, Yong Li, Myra PopejoyBackground We report an interim analysis of safety and efficacy of pemivibart in individuals with (cohort A) or without (cohort B) significant immunocompromise in the phase 3 CANOPY trial. Methods Eligible participants (≥18 years; negative for current SARS-CoV-2 infection) received 2 intravenous 4500-mg pemivibart infusions (cohort A) or were randomized 2:1 to receive blinded pemivibart or placebo
-
Responding to additional considerations regarding the risk of acute kidney injury with cefepime versus piperacillin-tazobactam in patients with septic shock. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-23
Asad E Patanwala,David E Nix,Thomas E Hills,Brian L Erstad -
Reassessing the Risk of Acute Kidney Injury with Cefepime Versus Piperacillin-Tazobactam in Septic Shock: Additional Considerations. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-23
Shio-Shin Jean,Chih-Cheng Lai -
Welcome to Ethics Rounds Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-23
Olivia Kates, Tim LaheyEthics is central to one-on-one and population-level infectious diseases care. To give home and voice to the full scope of infectious diseases ethics, from grand to granular, from bedside to global, we hereby inaugurate the Ethics Rounds section of Clinical Infectious Diseases.
-
Ethical Management of Challenging Behaviors in Hospitalized People Who Use Drugs Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-23
Christina Yen, Kinna Thakarar, Tim LaheyFrom drug use in the hospital to patient-directed discharges and threatening behavior, challenging behaviors arise frequently in inpatients with infectious complications of substance use disorders (SUDs). The management of such challenging behaviors can bring key ethical values into tension and be susceptible to clinician bias. Here, we characterize the ethical tensions that emerge in the management
-
Weekly Oral Cycling Antibiotic Treatment: A New Antibioprophylaxis Regimen for Recurrent UTIs. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-23
Virgile Veyrat,Aurélien Dinh,Clara Duran,Nathalie Dournon -
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-22
Nandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, Kathleen Chiotos, Amy L Dzierba, Arthur Y Kim, Greg S Martin, Jeffrey C Pearson, Amy Hirsch Shumaker, Lindsey R Baden, Roger Bedimo, Vincent Chi-Chung Cheng, Kara W Chew, Eric S Daar, David V Glidden, Erica J Hardy, Steven Johnson, Jonathan Z Li, Christine MacBrayne, Mari M Nakamura, Laura Riley, Robert W Shafer, Shmuel Shoham, Pablo Tebas, Phyllis C TienThis article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres
-
From Suspected to Rejected: Role of Serial Plasma mcfDNA Sequencing as a Diagnostic Adjunct in CIED Infections. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-21
Sarwat Khalil,M Rizwan Sohail -
Correction to: Serial Mass Screening for Tuberculosis Among Incarcerated Persons in Brazil. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-21
-
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-21
Konstantin Chumakov,Stanley A Plotkin -
Cost-Effectiveness Analysis of Testing Approaches for Diagnosis of Hepatitis C Among US Adults Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-21
Eric W Hall, Amy L Sandul, Saleem Kamili, Emily J Cartwright, Hasan Symum, Carolyn WesterBackground Diagnosis of infection with hepatitis C virus (HCV) is the first step to accessing curative treatment, yet many infected adults in the United States are unaware of their infection. Viral-first HCV testing strategies may improve diagnosis. We assessed the cost-effectiveness of several hepatitis C testing strategies compared with the currently recommended testing algorithm. Methods We used
-
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021 Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-21
Nayab Mehmood, Muhammad Masroor Alam, Yasir Arshad, Ribqa Akhtar, Adnan Khurshid, Ghulam Mujtaba, Lubna Rehman, Nighat Mushtaq, Bisma Sarfaraz, Muhammad Suleman Rana, Muhammad Usman, Massab Umair, Muhammad Salman, Salmaan Sharif, Zain Ul Abedin Khan, Mohammed Ahmed Soghaier, Syed Sohail Zahoor Zaidi, Muhammad Faraz Arshad MalikBackground To mitigate the risk of circulating vaccine-derived poliovirus type 2 (cVDPV2) establishment and associated paralytic cases, oral polio vaccine 2 was globally withdrawn from the routine immunization schedule in 2016, soon after the certification of wild poliovirus type 2 eradication. We investigated the epidemiology of cVDPV2 outbreak and impact of type 2 immunization response in Pakistan
-
Contamination of blood cultures drawn from arterial catheters versus venipuncture or venous catheters in critically ill patients: a systematic review and meta-analysis Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-21
Takatoshi Koroki, Motoki Fujii, Yuki Kotani, Takahiko Yaguchi, Taisuke Shibata, Chihiro Hirata, Naoki Okawa, Koshi Ota, Mayuko Tonai, Toshiyuki Karumai, Yuki Kataoka, Yoshiro HayashiBackground Arterial catheter-drawn blood culture sampling may reduce patient discomfort and healthcare providers’ workload. Guidelines discourage transcatheter blood culture collection due to contamination risks, mainly derived from data on venous catheter-drawn cultures. However, contamination rates of arterial catheter-drawn cultures have not been comprehensively evaluated compared with venipuncture-
-
Carbapenem-resistant Gram-negative bacilli bacteremia in Argentina (EMBARCAR): findings from a prospective, multicenter cohort study Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-20
Juan Pablo Balbuena, Ezequiel Cordova, Analia Mykietiuk, Javier Farina, Marcelo Gañete, Pablo Scapellato, María Inés Lespada, Esteban Nannini, Rosa Contreras, Eleonora Cunto, Laura Barcelona, Fernando Pasteran, Claudia Salgueira, Martin Hojman, Miriam Blanco, Horacio Lopez Alegre, William E Cox Fernandez, Cecilia Ezcurra, Dario Godoy, Maria A Biglia, Maria J Lopez Furst, Gustavo A Mendez, Maria F AguirreBackground Bloodstream infections (BSI) caused by carbapenem-resistant gram-negative bacilli (CR-GNB) are difficult-to-treat infections associated with high mortality. Outcomes of BSI due to CR-GNB may vary in different countries. Methods Prospective observational, multicentric study, including consecutive hospitalized index patients aged ≥18 years, with a positive blood culture for CR-GNB, between
-
Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among individuals with substance use disorders who are hospitalized in an integrated U.S. health system Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-20
Jennifer H Ku, Yuqian M Gu, Cheyne F Hoke, Hung-Fu Tseng, Yi Luo, Rulin C Hechter, Bradley K Ackerson, Cara D VarleyBackground Hepatitis A virus infection (HAV), hepatitis B virus infection (HBV), and tetanus are important vaccine-preventable infections among individuals with substance use disorder (SUD). Hospitalizations may represent opportunities for preventive care. Up-to-date data on screening and vaccination practices for this high-risk population are needed in these settings. Methods In a retrospective cohort
-
Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-20
Tom Loosli, Carolyn Bolton Moore, Lydia Buzaalirwa, Helen Byakwaga, İpek Çelikağ, Cleophas Chimbetete, Peter Vanes Ebasone, Jennifer Giandhari, Nuri Han, Jacqueline Huwa, Charles Kasozi, Adolphe Mafoua, Eugène Messou, Albert Minga, Guy Muula, Winnie Muyindike, Arcel Christ Massamba Ndala, Mamatha Sauermann, Aggrey Semeere, Lavanya Singh, Roger D Kouyos, Richard Lessells, Matthias EggerDolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
-
Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-16
Yewande Odeyemi, Aysun Tekin, Caitlin Schanz, Diana Schreier, Kristin Cole, Ognjen Gajic, Erin BarretoBackground Doxycycline is a frequently used alternative treatment for community-acquired pneumonia in hospitalized patients, but the evidence base is limited. The study aimed to compare outcomes in community-acquired pneumonia patients treated with doxycycline or azithromycin in combination with beta-lactams. Methods We evaluated patients with community-acquired pneumonia admitted to Mayo Clinic hospitals
-
Histoplasma antigenuria prevalence in patients with advanced HIV disease in Côte d’Ivoire: a prospective trial ancillary study Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-16
Aude Sturny-Leclère, Ugo Françoise, Anani D Badjé, Dea Garcia-Hermoso, Cyrielle Aka, Hervé Menan, Delphine Gabillard, Conrad K Muzoora, Maryline Bonnet, François-Xavier Blanc, Olivier Lortholary, Alexandre Alanio, Antoine A Adenis, Didier Laureillard, Fanny LanternierBackground Despite tuberculosis being a well-known concern in advanced HIV patients, the STATIS trial, which focused on its management, highlighted significant mortality rates. Histoplasmosis, a fungal disease endemic in sub-Saharan Africa, presents with similar clinical manifestations as of tuberculosis. Therefore, it may be prevalent and potentially responsible for deaths in advanced HIV patients
-
Effectiveness of a Home-based Approach to Child Contact Investigation and TPT Management by Community Health Workers in Ethiopia: A Pragmatic Cluster-randomized Trial Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-16
Nicole Salazar-Austin, Silvia Cohn, Bareng A S Nonyane, Christiaan Mulder, Fiseha Mulatu, Samuel Bayu, Moges Bizuayehu, Gidea Conradie, Akash Malhotra, Paul Phan, Natalia Hernandez Morfin, Stephanie Borsboom, Petros Mitiku, Demissu Fulas, Mulunesh Tulema, Jonathan E Golub, Richard E Chaisson, Gavin Churchyard, Ahmed BedruBackground Tuberculosis preventive treatment (TPT) is highly effective at preventing tuberculosis (TB) disease but is poorly implemented. We aimed to determine whether home-based contact management improves TPT uptake among close child contacts compared to the facility-based standard of care. Methods We conducted a pragmatic cluster-randomized trial among close contacts of TB clients aged <15 years
-
A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection: The Failure of a Procedure, not of a Therapy. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-15
Nadim Cassir,Nicolas Benech,Tatiana Galperine,Laurent Alric,Julien Scanzi,Alexandre Bleibtreu,Nathalie Kapel,Harry Sokol -
The Effect of Live-Virus Vaccines on Tests for Tuberculosis Infection During the US Immigration Medical Examination: Are Vaccines Causing False-Negative Results? Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-15
Joanna J Regan,Zanju Wang,Christina R PharesBACKGROUND It is not recommended to perform tuberculin skin tests (TSTs) or interferon-γ release assays (IGRAs) in the 4 weeks following live-virus vaccination because these vaccines are thought to increase the risk of false-negative results. METHODS We retrospectively analyzed TST and IGRA results for 158 484 US-bound immigrant and refugee children aged 2-14 years who received a required medical examination
-
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-14
Matthew R Davis, Julia E Kufel, Wesley D Kufel, Erin K McCreary, Louise-Marie Oleksiuk, Rachael Ours, Christine U Pham, Jennifer K Ross, Ethan A Smith, Michael J Trisler, Frank TverdekThis multicenter study highlights the critical role of ID pharmacists in supporting ID consult services, with 89% of 1,518 curbside inquiries from ID clinicians resulting in clinical management changes as recommended by the pharmacist. These findings emphasize the necessity of ID pharmacists in optimizing multidisciplinary patient care.
-
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-14
Astrid Wintering, Agnes Bonifacius, Sabine Tischer-Zimmermann, Ariana de Oliveira Mekonnen, Damaris Werner, Rebecca Schultze-Florey, Albert Heim, Rita Beier, Martin Sauer, Britta Eiz-Vesper, Britta Maecker-KolhoffHerpes simplex virus (HSV) reactivation and acyclovir resistance are common complications in immunocompromised individuals. We report a pediatric hematopoietic stem cell transplantation (HSCT) recipient who received HSV-1-specific T cells from a partially human leukocyte antigen (HLA) matched donor for severe acyclovir-resistant HSV-1 mucositis resulting in clinical improvement, reduced plasma viral
-
Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-13
Win Min Han, Lene Ryom, Caroline A Sabin, Lauren Greenberg, Matthias Cavassini, Alexander Egle, Claudine Duvivier, Ferdinand Wit, Cristina Mussini, Antonella d’Arminio Monforte, Antonella Castagna, Jose M Miro, Marc van der Valk, Fabrice Bonnet, Christian Pradier, Matthias Skocic, Raimonda Matulionyte, Marcel Stöckle, Nadine Jaschinski, Alisa Timiryasova, Joan Tallada, Felipe P Rogatto, Vani VannappagariBackground The impact of long-term virological suppression and CD4 count recovery on non-AIDS defining cancers (NADC) is unclear. We determined whether poor immune recovery was associated with incident cancer risk in people with HIV with virological suppression (VS). Methods Participants from the D:A:D and RESPOND collaborations in Europe and Australia who achieved ≥2 years of VS on ART between Dec
-
"I Didn't Know Him Before the Pandemic… Now He's on My Speed Dial": Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-13
Diana Valencia,Leslie Edwards,Libby Horter,Hannah Turner,Manpreet Kaur,Maitri Vaidya,Ty Johnson,Eli Briggs,Dana Wollins,Shu Phua,Arnold Y Chen,Suzanne Felt-Lisk,William A Werbel,Alice I Kim,Sarah Lim,John B Lynch,Mary M K Foote,Zanthia Wiley,Julie Vaishampayan,Pragna Patel,Scott SantibañezBACKGROUND Infectious diseases (ID) physicians play a crucial role in public health emergencies. Effective collaboration between public health agencies and healthcare providers is essential for a coordinated response. However, there is limited information on how ID physicians and health departments collaborate and which areas need to be improved. Here, we identify ways to enhance public health preparedness
-
Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United States Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-13
Arthur W Baker, Ricardo M La Hoz, Judith A Anesi, Jennie H Kwon, Anastasia I Wasylyshyn, Emily S Ford, Susan M Harrington, Melissa B Miller, David J Weber, Emily E Sickbert-Bennett, Thomas R Talbot, M Hong Nguyen, Kailey Hughes Kramer, Katelin B Nickel, Matthew J Ziegler, Doramarie Arocha, Charles Henderson, Yuliya Lokhnygina, Ahmed Maged, Salah Haridy, Barbara D Alexander, Jason E Stout, DeverickBackground Data on the epidemiology of healthcare facility-associated (HCFA) nontuberculous mycobacteria (NTM) are sparse. We performed a multicenter longitudinal cohort study of HCFA NTM epidemiology. Methods We retrospectively analyzed positive cultures for NTM performed from 2012 through 2020 within a network of 10 US academic hospitals and associated clinics. A unique NTM episode was defined as
-
Histoplasma antigen screening in advanced HIV disease. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-13
Ilan S Schwartz,Alessandro C Pasqualotto -
The Burden of Antimicrobial Resistant Bacteremia in Ontario: A Population-wide Analysis of Attributable Mortality from 110 Pathogen-Antibiotic Combinations Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-13
Kevin A Brown, Daniel J Fridman, Gary E Garber, Jennie Johnstone, Bradley J Langford, Valerie Leung, Derek MacFadden, Samir N Patel, Kevin L Schwartz, Beate Sander, Nick DanemanBackground Reliable information on the burden of antimicrobial resistance (AMR) is necessary to confront the threat of antimicrobial resistance. We sought to examine the association between AMR and mortality across cultured bacterial bloodstream pathogens in the province of Ontario, Canada. Methods We used linked microbiology data from 114 hospital, community, and public health laboratories to develop
-
Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-13
Deborah Konopnicki, Christine Gilles, Yannick Manigart, Patricia Barlow, Anca Reschner, Coca Necsoi, Marc Delforge, Davy Vanden Broeck, Nicolas Dauby, Stéphane De WitBackground WHO recommends 2 doses of HPV vaccine for adults without HIV but 3 doses in persons with HIV. There are no immunogenicity data on the 2 doses schedule in women with HIV (WWH). Methods Prospective study comparing 2 (month (M) 0,6) versus 3 (M 0,2,6) doses of 9-valent (9v) vaccine (Gardasil9®MSD) in WWH (15-40 years), on antiretrovirals with HIVRNA<400cp/ml; enrollment 2018-2021. After an
-
HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record Based Cohort Study. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-12
Kellie L Hawkins,Dima Dandachi,Zoe Verzani,M Daniel Brannock,Colby Lewis,Sajjad Abedian,Sohrab Jaferian,Shannon Wuller,Jennifer Truong,Margot Gage Witvliet,Gretchen Dymond,Hemalkumar B Mehta,Payal B Patel,Elaine Hill,Mark G Weiner,Thomas W Carton,Rainu Kaushal,Elen Feuerriegel,Huong G Tran,Kristen Marks,Carlos R Oliveira,Edward M Gardner,Igho Ofotokun,Roy M Gulick,Kristine M Erlandson,,People with HIV may be at increased risk for long COVID after acute SARS-CoV-2 infection. We investigated the association between HIV and long COVID in two large electronic health record databases. Using data from the Patient-Centered Clinical Research Network (PCORnet) and the National Clinical Cohort Collaborative (N3C) from 1/1/2018 to 4/30/2024, our analytic sample included individuals aged ≥21
-
Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-12
Joshua M Chevalier, Megan A Hansen, Benjamin Blumel, Veronicah Chuchu, Birgitta Gleeson, Cecilia Ferreyra, Shaukat Khan, Brooke E Nichols, Kyra H GrantzBackground Limited diagnostic access in resource-limited settings contributes to poor health outcomes among bacterial sepsis patients and the spread of antimicrobial resistance (AMR). Molecular diagnostic profiling of AMR may enable faster targeting of antibiotic therapies, improving clinical outcomes, reducing AMR development, and saving costs. Methods We modeled the impact of a culture-dependent
-
On the optimal treatment of Metallo-Beta-Lactamase-producing Enterobacterales infections using aztreonam and avibactam. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-12
Yehuda Carmeli,José Miguel Cisneros,Mical Paul,Joseph Chow,George L Daikos -
Revisiting REVISIT: The Case for Ceftazidime/avibactam Plus Aztreonam. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-12
Pranita D Tamma,Thomas P Lodise,Maria F Mojica,Federico Perez,Robert A Bonomo -
Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-09
Jacob A M Stadler, Johanna J Kuhlin, Síle F Molloy, Nomfuneko N Mtwa, Cindy C Hayes, Gary G Maartens, Robin R Warren, Graeme G Meintjes, Sean S WassermanBackground Bedaquiline-based oral short-course regimens (SCR) for rifampicin-resistant tuberculosis (RR-TB) are highly effective in clinical trials but outcomes in programmatic settings may be more modest. We evaluated clinical and bacteriological outcomes with a seven-drug, linezolid-containing SCR in a high-burden programmatic setting. Methods This prospective cohort study enrolled adults with newly
-
Correction to: Diagnosis and Management of Spinal Implant Infections. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-08
-
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016-2022 Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-06
Silvia S Chiang, Jonathon R Campbell, Daniele Maria Pelissari, Márcia C Bellotti de Oliveira, Anna Cristina C Carvalho, Sylvia M LaCourse, Clemax C Sant’AnnaBackground Over 200,000 pregnant people fall ill with tuberculosis (TB) annually. Little is known about the impact of pregnancy on TB outcomes. Methods This study used surveillance data from Brazil’s Ministry of Health. We included women 11-49 years old newly diagnosed with drug-susceptible TB disease between 2016-2022, treated with a first-line anti-TB regimen, and with a known treatment outcome.
-
Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic over 96 Weeks: An Interrupted Time Series Analysis Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-06
Matthew A Spinelli, Megan J Heise, Jorge Roman, Jason Bena, Michael P Barry, Susan P Buchbinder, Hyman M ScottDoxycycline post-exposure prophylaxis (doxy-PEP) reduced bacterial sexually transmitted infection (STI) incidence in a sexual health clinic over 96 weeks (n=4,592; 2,524 on doxy-PEP), particularly for chlamydia and syphilis, with smaller effects for gonorrhea. Continued surveillance for gonorrhea and antibiotic resistance is essential to evaluate doxy-PEP’s long-term effectiveness.
-
Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients with HIV in the United States Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-06
Puja Nambiar, Tao Liang, Nazzarena Labo, Jonathan Hand, Emily A Blumberg, Meenakshi M Rana, Sander Florman, Brandy Haydel, Michele I Morris, Joanna Schaenman, Moreno M S Rodrigues, William A Werbel, Mary G Bowring, Rachel J Friedman-Moraco, Peter Stock, Valentina Stosor, Shikha Mehta, Alexander J Gilbert, Nahel Elias, Sapna A Mehta, Catherine B Small, Ghady Haidar, Maricar Malinis, Marcus R PereiraBackground Due to high prevalence of Kaposi Sarcoma (KS)-Associated Herpesvirus (KSHV) among people with HIV, KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+). Methods Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D-) using a 30-antigen multiplex assay within three multicenter
-
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020 Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-05
Justin Z Amarin, Ariana P Toepfer, Andrew J Spieker, Haya Hayek, Tess Stopczynski, Yasmeen Z Qwaider, Laura S Stewart, James D Chappell, Mary Allen Staat, Elizabeth P Schlaudecker, Geoffrey A Weinberg, Peter G Szilagyi, Janet A Englund, Eileen J Klein, Marian G Michaels, John V Williams, Rangaraj Selvarangan, Christopher J Harrison, Leila C Sahni, Vasanthi Avadhanula, Meredith L McMorrow, Heidi L MolineBackground Risk factors for severe respiratory syncytial virus (RSV) illness include early infancy, premature birth, and underlying medical conditions. However, the clinical significance of respiratory viral co-detection is unclear. We compared the clinical outcomes of young children with RSV-only detection and those with RSV viral co-detection. Methods We conducted active, population-based surveillance
-
HIV RNA testing to monitor oral PrEP use does not add clinical value: a real-world cohort study—United States, 2019-2023 Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-05
Weiming Zhu, Kevin Delaney, Ya-lin A Huang, Rupa R Patel, Athena P Kourtis, Karen W HooverBackground The 2021 update of the CDC clinical guidelines for HIV preexposure prophylaxis (PrEP) recommended both antigen/antibody (Ag/Ab) and RNA testing at PrEP initiation and routine follow-up. We assessed real-world utilization and performance of HIV tests among oral PrEP users. Methods An oral PrEP user cohort was constructed using the HealthVerity database that included linked diagnoses, laboratory
-
Virus-specific T-cell therapy for prophylaxis and treatment of cytomegalovirus infections after transplantation: a scoping review Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-02
J S T Fung, R C Wright, D K Bharaj, A Alghamdi, D Hesson, J S Delisle, L Schweitzer, R K Avery, S BelgaBackground Cytomegalovirus (CMV) infection is a leading complication following hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Virus-specific T-cells (VST) have been used for the prophylaxis and treatment of CMV infections. We conducted a scoping review to catalogue and characterize the existing literature. Methods Systematic searches were performed in collaboration with
-
State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-05-01
Zachary A Yetmar, Paige K Marty, Josh Clement, Cyndee Miranda, Nancy L Wengenack, Elena BeamNocardiosis is an uncommon yet potentially devastating infection. Nocardia tends to affect individuals with chronic lung disease or immunocompromising conditions, 2 groups increasing in number. Incidence of nocardiosis is likely to increase as well, and it is vital to have an approach to this complex disease. Here, we aim to review the presentation, diagnosis, and management of Nocardia in the modern
-
A Sexually Active Man With an Erythematous Rash. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-30
Shauna H Gunaratne,Jason Zucker -
Acute Unilateral Vision Loss in a Young Woman. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-30
Megan Lane,Prishanya Pillai,Amira Abbas,Benjamin Osborne,Amanda Blair Spence,Princy Kumar -
Responsible use of doxycycline for STI prevention includes both recognizing its benefits and planning for antimicrobial resistance monitoring. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-30
Troy Grennan,Mark W Hull -
Evidence for selection of doxycycline resistance in Staphylococcus aureus in DoxyPrEP study. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-30
Sheeba Manoharan-Basil,Thibaut Vanbaelen,Chris Kenyon -
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact. Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-30
Alexander J Sundermann,Praveen Kumar,Marissa P Griffith,Kady D Waggle,Vatsala Rangachar Srinivasa,Nathan Raabe,Emma G Mills,Hunter Coyle,Deena Ereifej,Hannah M Creager,Ashley Ayres,Daria Van Tyne,Lora Lee Pless,Graham M Snyder,Mark Roberts,Lee H HarrisonBACKGROUND Current methods are insufficient alone for outbreak detection in hospitals. Real-time genomic surveillance offers the potential to detect otherwise unidentified outbreaks. We initiated and evaluated the Enhanced Detection System for Healthcare-associated Transmission (EDS-HAT), a real-time genomic surveillance program for outbreak detection and mitigation. METHODS This study was conducted
-
Impact of a Collaboration-Focused Intervention to Prevent Healthcare-Associated Infections Before and During the Coronavirus Disease 2019 Pandemic Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-29
Karen M Jones, M Todd Greene, Jennifer Meddings, Julia Mantey, Sarah L Krein, Molly Harrod, Ana Montoya, John P Mills, Lona ModyBackground Nursing home (NH) residents are susceptible to healthcare-associated infections (HAIs). Alignment among NHs, hospitals, and health departments is critical for effective implementation of infection prevention efforts. We tested a collaborative model that engaged hospitals and NHs to reduce infections among NH residents. Methods We recruited 92 NHs and 15 hospitals over four 12-month cohorts
-
Transmitted Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-29
Jingjing Hao, Xiu Liu, Dong Wang, Hongping Hu, Fangyuan Li, Yantong Li, Jing Hu, Chang Song, Yuhua Ruan, Yi Feng, Zheng Wang, Yiming Shao, Lingjie Liao, Hui XingBackground Transmitted drug resistance (TDR) may compromise the effect of antiretroviral therapy (ART), highlighting the necessity for continuous monitoring. Methods The study was conducted across 31 provincial-level administrative divisions of China. Demographic information and blood samples were collected from participants at diagnosis of human immunodeficiency virus (HIV) infection between April
-
Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-28
Leyla Larsson, Claire J Calderwood, Edson T Marambire, Kathrin Held, Denise Banze, Alfred Mfinanga, Karlos Madziva, Phoebe Walsh, Joseph Jacob, Francisco Trinchan Fernandez, Patrick Lungu, Anita Mesic, Celso Khosa, Lilian T Minja, Junior Mutsvangwa, Madhavi Bhargava, Michael Lauseker, Rishi K Gupta, Norbert Heinrich, Katharina KranzerBackground Studies have demonstrated an inverse log-linear relationship between body mass index (BMI) and tuberculosis incidence. However, a person’s BMI is dynamic and longitudinal changes may be more informative than cross-sectional assessments. We evaluate the association between cross-sectional and changing BMI and risk of tuberculosis and describe longitudinal trajectories in a high-risk cohort
-
Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity Clin. Infect. Dis. (IF 8.2) Pub Date : 2025-04-26
Alyssa Christensen, Zachary Nelson, Sally Gustafson, Rachel Stoecker, Brent Footer, Nicole Trower, Laura Grangaard Johnson, Elizabeth B Hirsch, Stefan Collinet-Adler, Maxx Enzmann, Ethan Ryberg, Sarah Rebecca PeglowBackground There is limited data to support routine remdesivir use in the contemporary era of SARS-CoV-2 with widespread seropositivity. Methods A restriction of remdesivir among adult immunocompetent patients was implemented across an 8-hospital health system. A pre-post quasi-experimental design was used to compare patients 12 months pre-intervention (June 2022 - May 2023) to 12 months post-intervention